Limited ESA Use in COVID-19 Patients Recommended
Infection with the virus that causes COVID-19, coupled with use of erythropoiesis-stimulating agents may result in additive prothrombotic effects, according to the authors.
All articles by Natasha Persaud
Molidustat Noninferior to Darbepoetin in Nondialysis CKD
In 2 Japanese trials of nondialysis patients, molidustat proved noninferior to darbepoetin alfa, an erythropoiesis-stimulating agent, in correcting and maintaining hemoglobin levels over 36 weeks.
ADT Use for Prostate Cancer Increases Anemia Risk
Treatment with androgen deprivation therapy alone is associated with increased risks for anemia compared with radical prostatectomy alone, a study found.
Anemia Severity May Influence Vascular Access Outcomes, Mortality
In a study of chronic kidney disease patients undergoing vascular access surgery for hemodialysis, severe preoperative anemia was associated with worse outcomes.
-
Loading...
-
Loading...
